Shares of American Renal Associates Holdings Inc. (NYSE:ARA) traded down 2% on Thursday . The company traded as low as $23.09 and last traded at $23.30, with a volume of 184,050 shares. The stock had previously closed at $23.78.

Several brokerages have commented on ARA. Zacks Investment Research upgraded shares of American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Thursday. Leerink Swann began coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Barclays PLC began coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued an “overweight” rating and a $33.00 price objective for the company. Goldman Sachs Group Inc. began coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, Wells Fargo & Co. began coverage on shares of American Renal Associates Holdings in a report on Monday, May 16th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.20.

The firm’s 50-day moving average price is $0.00 and its 200 day moving average price is $0.00. The firm has a market capitalization of $517.70 million and a price-to-earnings ratio of 11.87.

American Renal Associates Holdings (NYSE:ARA) last posted its earnings results on Tuesday, August 9th. The company reported ($0.75) earnings per share for the quarter. The firm had revenue of $185.60 million for the quarter, compared to analysts’ expectations of $161.50 million. On average, analysts expect that American Renal Associates Holdings Inc. will post $0.88 EPS for the current fiscal year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.